Substituted urea neuropeptide Y Y5 receptor antagonists

Abstract

Compounds represented by structural formula I 1 including its N-oxides wherein 2 R1 is H or (C1-C6)alkyl; R2 is H, (C1-C6)alkyl, (C3-C9)cycloalkyl or (C3-C7)cycloalkyl(C1-C6)alkyl; 3 Z is OR10, —N(R9)(R10) or —NH2; j is 0, 1 or 2; k is 1 or 2; l is 0, 1 or 2; m is 0, 1 or 2; R4 is 1-3 substituents independently selected from the group consisting of H, —OH, halogen, haloalkyl, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, —CN, —O(C1-C6)alkyl, —O(C3-C7)cycloalkyl, —O(C1-C6)alkyl(C3-C7)cycloalkyl, —S(C1-C6)alkyl, —S(C3-C7)cycloalkyl, —S(C1-C6)alkyl(C3-C7)cycloalkyl, —NH2, —NR9R10, —NO2, —CONH2, —CONR9R10 and NR2COR10; R5 is 1-3 substituents independently selected from the group consisting of H, halogen, —OH, haloalkyl, haloalkoxy, —CN, —NO2, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, —O(C1-C6)alkyl, —O(C3-C7)cycloalkyl, —O(C1-C6)alkyl(C3-C7)cycloalkyl, —CONH2 and —CONR9R10; R6 is —SO2(C1-C6)alkyl, —SO2(C3-C7)cycloalkyl, —SO2(C1-C6)alkyl(CC7)cycloalkyl, —SO2(C1-C6)haloalkyl, —SO2(hydroxy(C2-C6)alkyl), —SO2(amino(C2-C6)alkyl), —SO2(alkoxy(C2-C6)alkyl), —SO2(alkylamino(C2-C6)alkyl), —SO2(dialkylamino(C2-C6)alkyl), —SO2(aryl), —SO2(heteroaryl), —SO2(aryl(C2-C6-alkyl), SO2N H2, —SO2N R9R10, —C(O)C1-C6alkyl, —C(O)C3-C7cycloalkyl, —C(O)aryl, —C(O)heteroaryl, —C(O)NR9R10, —C(O)NH2, —C(S)NR9R10, —C(S)NH2, aryl, heteroaryl, —(CH2)nC(O)NH2, —(CH2)nC(O)NR9R10, —C(═NCN)alkylthio, —C(═NCN)NR9R10, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl or —C(O)OR9, N=1 to 6; R7=H or alkyl; R8 is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, aryl, heteroaryl, —SO2(C1-C6)alkyl, —SO2(C3-C7)cycloalkyl, —SO2(C1-C6) alkyl(C3-C7)cycloalkyl, —SO2(C1-C6)haloalkyl or —SO2(aryl); R9 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, aryl(C1-C6)alkyl, aryl or heteroaryl; and, R10 is hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, aryl(C1-C6)alkyl, aryl or heteroaryl; or a pharmaceutically acceptable addition salt and/or hydrate thereof, or prodrug thereof, or R9 and R10 taken together can form a 4-7 membered ring containing 1 or 2 heteroatoms; or where applicable, a geometric or optical isomer or a racemic mixture thereof, are claimed, as well as additional novel compounds; also claimed are pharmaceutical compositions and methods of using the aforesaid compounds in the treatment of obesity, eating disorders such as hyperphagia and diabetes.

Dependencies are inferred from the claim text.